Joseph F. Goldberg, MD, is clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai in New York, and is director of the Affective Disorders Research Program at Silver Hill Hospital in New Canaan, CT. Dr. Goldberg attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency in psychiatry and fellowship in psychopharmacology at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site principal investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 170 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as 3 books on bipolar disorder and psychopharmacology. He serves on the board of directors for the American Society of Clinical Psychopharmacology and serves on the editorial boards for a number of peer-reviewed journals. He has been awarded research funding from NARSAD, NIMH, the Theodore and Vada Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a distinguished fellow of the American Psychiatric Association, is listed in Best Doctors in America, and is a Castle Connolly Top Doctor in Psychiatry.

Thomas E. Schlaepfer, MD, is vice chair of the Department of Psychiatry and Psychotherapy and professor of psychiatry at the University Hospital Bonn, Bonn, Germany; professor of psychiatry and mental hygiene (part time) at The Johns Hopkins University School of Medicine, Baltimore, MD; and dean of medical education at the University of Bonn, Bonn, Germany. He received his medical training at the University of Bern, Bern, Switzerland. He completed internship and residence training at the University Hospital Bern and The Johns Hopkins Hospital. Before assuming his current position, he completed a fellowship in psychiatric neuroimaging at The Johns Hopkins University and directed the Division of Psychiatric Neuroimaging at the University Hospital Bern, Switzerland.

Dr. Schlaepfer focused the research of his group on translational, functional neuroimaging, and clinical effects of neuromodulation interventions (including repetitive transcranial magnetic stimulation, vagus nerve stimulation, magnetic seizure therapy, and deep brain stimulation) for treatment-resistant major depression. After the first human application in the year, his group developed the clinical use of magnetic seizure therapy (MST) for depression and more recently the hypothesis-guided therapeutic use of deep brain stimulation of parts of the human reward system in the same disorder.